Use of antioxidant could ameliorate the negative impact of etoposide on human sperm DNA during chemotherapy

• Type: Article in International Scientific Journal
• Date: 2020

Authors

Rabaca, A (Author) Other; Ferreira, C (Author) Other; Bernardino, R (Author) Other; Alves, M (Author) Other; Oliveira, P (Author) FMUP; Viana, P (Author) Other; barros, a (Author) FMUP; sousa, m (Author) ICBAS; Sa, R (Author) ICBAS

Journal

Title: Reproductive BioMedicine Online

Vol. 40

Pages: 856-866

ISSN: 1472-6483

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 7 Citations

Scopus - 7 Citations

Other information

Authenticus ID: P-00S-1WS

DOI: 10.1016/j.rbmo.2020.01.029

Abstract (EN): Research question: A previous study showed that N-acetylcysteine (NAC), used after in-vitro exposure to the gonadotoxic chemotherapeutic drug etoposide, has the ability to decrease DNA damage in human spermatozoa; however, it showed no benefit when used before exposure. This study aimed to evaluate the impact of the NAC on the preservation of sperm quality during in-vitro exposure to etoposide. Design: Twenty semen samples were submitted to four experimental conditions: control, NAC-only incubation, etoposide-only incubation, and concomitant etoposide and NAC incubation. After in-vitro incubation, semen parameters, sperm chromatin condensation, sperm DNA fragmentation, sperm oxidative stress and sperm metabolism were used to evaluate the role of NAC in protecting human spermatozoa from etoposide. Results: Etoposide did not affect semen parameters, nor did it cause sperm oxidative damage or alterations in glycolytic profile. However, it induced chromatin decondensation and DNA fragmentation, which were fully prevented by NAC. Conclusions: NAC was able to protect sperm DNA integrity during etoposide treatment in vitro, suggesting that NAC may be useful as an adjuvant agent in preserving male fertility during chemotherapy treatments.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 11